Compare OPLN & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPLN | PBLS |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.6B |
| IPO Year | 2008 | 2026 |
| Metric | OPLN | PBLS |
|---|---|---|
| Price | $35.46 | $40.42 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $32.00 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 333.6K |
| Earning Date | 05-05-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $1,934,500,000.00 | N/A |
| Revenue This Year | $9.43 | N/A |
| Revenue Next Year | $6.80 | N/A |
| P/E Ratio | $51.82 | ★ N/A |
| Revenue Growth | ★ 8.16 | N/A |
| 52 Week Low | $25.81 | $25.56 |
| 52 Week High | $42.69 | $41.49 |
| Indicator | OPLN | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.79 | 63.79 |
| Support Level | $34.19 | $37.88 |
| Resistance Level | $35.92 | $41.49 |
| Average True Range (ATR) | 0.92 | 2.18 |
| MACD | 0.17 | -0.18 |
| Stochastic Oscillator | 57.30 | 71.48 |
Openlane Inc provides a digital marketplace for used vehicles, connecting sellers and buyers in North America and Europe for fast and transparent transactions. Its services include financing, repossessions, repairs, transportation, warranty, and inventory management. The company operates used-vehicle auctions and has two main segments: Marketplace and Finance, with majority revenue coming from the Marketplace segment, which to used vehicle remarketing, including marketplace services, remarketing, or make ready services and all are interrelated, synergistic elements along the auto remarketing chain. The Finance segment, through AFC engaged in business of providing short-term, inventory-secured financing to independent vehicle dealers.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.